X4 Pharmaceuticals stock falls 1.59 percent as Q2 revenue rises
Published on 10/05/2026 at 15:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
X4 Pharmaceuticals stock (ISIN US98420X2027) was trading at USD 2.79 on Nasdaq on October 5, 2026, down USD 0.04 or 1.59 percent from the previous close. The latest reported quarter gives the market a sharper operating comparison: Q2 2026 revenue reached USD 8.806 million, up from USD 2.708 million in Q1.
Revenue jumps in Q2
Investing.com reported on August 6, 2026, that X4 posted Q2 earnings per share of negative USD 0.13 against a consensus loss of USD 0.19. The quarter's revenue of USD 8.806 million also exceeded the USD 2.28 million forecast cited on the same results page.
The sequential revenue increase was paired with a smaller net loss. X4 reported a net loss of USD 16.157 million in Q2, compared with USD 20.241 million in Q1, while operating loss narrowed from USD 20.306 million to USD 16.391 million.
Analysts see a wide gap
MarketBeat reported on September 13, 2026, that six analysts held a Moderate Buy consensus, consisting of four Buy ratings, one Hold and one Sell. The average 12-month price target was USD 11.25, which lies 303.2 percent above the USD 2.79 Nasdaq price on October 5, 2026.
The spread reflects the distinction between commercial progress and profitability. X4's Q2 net loss remained USD 16.157 million, and the company continues to fund development of mavorixafor while expanding its commercial and clinical programs.
Mavorixafor remains central
On its investor-relations page, X4 Pharmaceuticals describes mavorixafor as its orally available CXCR4 antagonist marketed in the United States as XOLREMDI. The company also says it is conducting the global Phase 3 4WARD trial in chronic neutropenic disorders and that the FDA has granted the program Fast Track designation.
For investors, the central test is whether the Q2 revenue base can expand while operating losses decline. The latest figures show revenue growth of USD 6.098 million from the preceding quarter, but the company still reported negative earnings per share of USD 0.13 for Q2.
Stock trades near yearly low
X4 Pharmaceuticals stock was trading at USD 2.79 on Nasdaq at 9:51 a.m. ET on October 5, 2026. Its 52-week range was USD 2.75 to USD 4.83, placing the quote USD 0.04 above the yearly low and USD 2.04 below the high.
X4 Pharmaceuticals stock facts
- Company: X4 Pharmaceuticals, Inc.
- ISIN: US98420X2027
- Ticker: XFOR
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 9:51 a.m. ET): USD 2.79
- Market capitalization: USD 262.7 million (as of October 5, 2026)
- 52-week range: USD 2.75-4.83 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Russell 2000
